Document:

Exhibit

EXHIBIT 10.1

SECOND AMENDMENT TO LETTER AGREEMENT

This Second Amendment (“Second Amendment”) is entered into as of June 21, 2019 by and between Las Vegas Sands Corp., a Nevada corporation ("LVSC"), and Las Vegas Sands, LLC, a wholly owned subsidiary of LVSC (together with LVSC, the “Company”) and Lawrence A. Jacobs (“you”) for the purpose of amending, changing and modifying terms of that certain letter agreement between the Company and you, dated August 23, 2016 (the “Agreement”), and the First Amendment to the Agreement dated October 9, 2018 (“First Amendment”), in accordance with Section 18 of the Agreement.  The reason for this Second Amendment is your desire to pursue other opportunities and interests and the Company’s desire for you to continue your employment beyond July 31, 2019.  Therefore, we have agreed to this Second Amendment to provide for an orderly transition of your duties and to allow you to depart the Company earlier than anticipated in the Agreement.

In consideration of the mutual promises, covenants, conditions and provisions contained herein, the Company and you agree as set forth below.

1.Defined Terms.  Capitalized terms that are used but not defined in this Second Amendment shall have the meanings assigned to those terms in the Agreement.  

2.Term.  Section 3 (Term) of the Agreement as amended by the First Amendment is deleted in its entirety and replaced with the following language:

“3.    Term.

		
	(a)
	The term of your employment under this Agreement shall commence as of September 6, 2016 and at anytime after August 1, 2019, shall terminate upon two (2) weeks’ written notice to you from the Company unless terminated sooner as provided under the terms of the Agreement.  Effective as of January 1, 2020, you may also terminate this Agreement upon two (2) weeks’ written notice to the Company.

		
	(b)
	In consideration of this Second Amendment, the Company will pay you a one-time retention bonus in the amount of One Million Two Hundred Sixty Thousand Eight Hundred Thirty-Three Dollars ($1,260, 833.00), subject to applicable withholdings, payable as of the first payroll period after August 1, 2019.

		
	(c)
	Upon notice of termination by either you or the Company in accordance with subparagraph (a) above, you shall be entitled to receive:

		
	(i.)
	A pro rata payment of the amount of your Bonus Incentive for 2019 measured from August 1, 2019, i.e., a pro rata portion of $370,834.00, (subject to withholdings), payable within the next payroll period following termination of employment; and

		
	(ii.)
	subject to approval by the Compensation Committee of the Company’s Board of Directors, accelerated vesting of remaining unvested options awarded and scheduled to vest on September 6, 2019 and September 6, 2020, as set forth in Section 6 of the Agreement; and

1

		
	(iii.)
	reimbursement for expenses incurred, but not paid prior to notice of termination, subject to receipt of supporting information by the Company consistent with Company policy; and

		
	(iv.)
	such other compensation and benefits as may be required by applicable law.”

3.Other Activities.  Notwithstanding anything in the Agreement to the contrary, you shall be permitted during the Term to engage in other activities that do not compete with the Company and do not interfere with your duties.  These other activities include, but are not limited to, joining the board of other companies or entities that do not compete with the Company, and associating with a law firm in an “Of Counsel” position so long as the law firm is not actively representing any other person or entity in a matter adverse to the Company.

4.Transitioning of Duties.  At any time during the Term, you shall assist with the transitioning of your position as Executive Vice President and Global General Counsel to a successor, including, but not limited to, assisting in the recruitment of your successor as requested, and transitioning some or all of your status, position, duties or responsibilities, in accordance with the directions of the Company’s Chairman & CEO, or his designee.

5.Amendment and Transitioning Are Not Good Reason or without Cause.  You acknowledge and agree that (a) this Second Amendment and any of the circumstances and/or negotiations leading up to this Second Amendment will not be construed so as to be the basis for a termination of your employment by you for Good Reason or by the Company without Cause and (b) notwithstanding anything to the contrary in Section 13b. of the Agreement, the transitioning set forth in Section 4 of this Second Amendment shall not constitute Good Reason or termination by the Company without Cause.

6.Entire Agreement.  This Second Amendment together with the Agreement and the First Amendment contain the entire agreement between the Company and you with respect to the subject matter hereof and no representations, oral or written, are being relied upon by either the Company or you in executing this Second Amendment other than the express representations of this Second Amendment, and the Agreement and the First Amendment.  As authorized by the Company’s Compensation Committee, any executive officer of the Company may execute this Second Amendment on the Company’s behalf.

7.Original Agreement.  Except as expressly modified by this Second Amendment, the terms and conditions of the Agreement are, and shall continue to remain, in full force and effect.  In the event of a conflict between the terms of this Second Amendment and the Agreement or the First Amendment, the terms of this Second Amendment shall control. 

2

The Company and you have read, understood, and duly executed this Amendment by their signatures, effective June 21, 2019.

	
					
	LAWRENCE A. JACOBS
	 
	LAS VEGAS SANDS CORP.

	 /s/ Lawrence A. Jacobs
	 
	By: 
	/s/ Robert G. Goldstein

	 
	 
	 
	Name:
	Robert G. Goldstein

	 
	 
	 
	Title:
	President & COO

	 
	 
	 
	 
	 

	 
	 
	 
	LAS VEGAS SANDS, LLC

	 
	 
	 
	By: 
	/s/ Robert G. Goldstein

	 
	 
	 
	Name:
	Robert G. Goldstein

	 
	 
	 
	Title:
	President & COO

3Exhibit 10.1

 

SECOND AMENDMENT TO ASSIGNMENT AGREEMENT

 

THIS SECOND AMENDMENT
TO ASSIGNMENT AGREEMENT (this “Amendment”), dated June 24, 2019, is entered into by and between Xenetic
Biosciences, Inc., a Nevada corporation (“Buyer”), and OPKO PHARMACEUTICALS, LLC (“OPKO”).

 

RECITALS

 

WHEREAS, Buyer
and OPKO previously entered into that certain Assignment Agreement, dated as of March 1, 2019, as amended (the “Assignment
Agreement”);

 

WHEREAS, pursuant
to Section 9.09 of the Assignment Agreement, the Assignment Agreement may be amended, modified or supplemented by an agreement
in writing signed by Buyer and OPKO; and

 

WHEREAS, Buyer
and OPKO desire to amend the Assignment Agreement by entering into this Amendment.

 

NOW, THEREFORE,
in consideration of the premises, the mutual covenants set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.               
Definitions. Capitalized terms used herein and not defined herein shall have the meaning ascribed to such terms as
set forth in the Assignment Agreement and all references to Sections shall mean the Sections of the Assignment Agreement unless
reference is made to another document.

 

2.               
Amendment to Assignment Agreement. The Assignment Agreement is hereby amended as follows:

Section 8.01.
Sections 8.01(b)(ii) and (c)(ii) are amended to change the date referenced therein of July 1, 2019 to July 15, 2019.

 

3.               
Assignment Agreement Otherwise Unchanged. Except as expressly provided herein, the Assignment Agreement shall remain
unchanged and in full force and effect. Each reference to “this Agreement” or “the Assignment Agreement”
and words of similar import in the Assignment Agreement and in the agreements and other documents contemplated by the Assignment
Agreement shall be a reference to the Assignment Agreement, as amended hereby, and as the same may be further amended, restated,
supplemented and otherwise modified and in effect from time to time.

 

4.               
Ratification. In all respects not inconsistent with this Amendment, Buyer and OPKO hereby ratify and affirm the Assignment
Agreement as amended hereby.

 

5.               
Miscellaneous. This Amendment shall be binding upon and inure to the benefit of each party to the Assignment Agreement
and its successors and permitted assigns. The interpretation and construction of this Amendment, and all matters relating hereto,
shall be governed by the laws of the State of Delaware applicable to agreements executed and to be performed solely within such
State and without regard to the conflict of laws rules thereof. The headings in this Amendment are for reference only and shall
not affect the meaning or interpretation of this Amendment. This Amendment may be executed in counterparts, each of which is deemed
an original, but all of which constitute one and the same instrument. Delivery of an executed counterpart of this Amendment electronically,
via email or .pdf, or by facsimile shall be effective as delivery of an original executed counterpart of this Amendment.

 

 

 

    	 	1	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amendment as of the date and year first set forth above.

 

 

	 	BUYER:
	 	 
	 	XENETIC BIOSCIENCES, INC.
	 	 
	 	 
	 	By: /s/ James Parslow
	 	Name: James Parslow
	 	Title:   Chief Financial Officer
	 	 
	 	 
	 	 
	 	OPKO:
	 	 
	 	OPKO PHARMACEUTICALS, LLC
	 	 
	 	By: /s/ Steven D. Rubin
	 	Name: Steven D. Rubin
	 	Title:   Executive Vice President

 

 

 

 

 

 

 

 

 

 

 

[Signature Page to Second Amendment to
ASSIGNMENT Agreement]

 

    	 	2EX-4.1

 Exhibit 4.1 
  

 

	
	

 Exhibit 4.1 BB INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 10806X 10 2 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This
certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF BridgeBio Pharma, Inc. transferable on the books of the corporation in person or by duly authorized attorney upon surrender of
this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers.
Dated: CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER TREASURER & SECRETARY COUNTERSIGNED AND REGISTERED: AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT AND REGISTRAR BY: AUTHORIZED SIGNATURE

 

 
The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and
relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the
Corporation’s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN,OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM –    as
tenants in common TEN ENT –    as tenants by the entireties JT TEN –    as joint tenants with right
of                survivorship and not as tenants                in common COM PROP
–    as community property UNIF GIFT MIN ACT – Custodian (Cust)                (Minor) under Uniform Gifts to Minors Act (State) UNIF TRF
MIN ACT – Custodian (until age ) (Cust) 
(Minor) under Uniform Transfers to Minors Act (State) Additional abbreviations may also be used though not in the
above list. FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s) unto PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) shares of the capital
stock represented by within Certificate, and do hereby irrevocably constitute and appoint attorney-in-fact to transfer the said stock on the books of the within named
Corporation with full power of the substitution in the premises. Dated X X 
Signature(s) Guaranteed: NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH
THE NAME AS WRITTEN UPON THE    FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. By 
THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15. GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]